0000950170-24-070566.txt : 20240607 0000950170-24-070566.hdr.sgml : 20240607 20240607160011 ACCESSION NUMBER: 0000950170-24-070566 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240605 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38327 FILM NUMBER: 241029132 BUSINESS ADDRESS: STREET 1: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 8-K 1 cue-20240605.htm 8-K 8-K
0001645460false00016454602024-06-052024-06-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2024

Cue Biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-38327

47-3324577

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

40 Guest Street

Boston, Massachusetts

02135

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 949-2680

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

CUE

 

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 5, 2024, Michael J. Fox was appointed to the board of directors (the “Board”) and the Compensation Committee of the Board of Cue Biopharma, Inc. (the “Company”), following the recommendation of the Corporate Governance and Nominating Committee of the Board.

 

There are no arrangements or understandings between Mr. Fox and any other persons pursuant to which Mr. Fox was selected as a member of the Board, and there are no transactions between Mr. Fox and the Company that would be reportable under Item 404(a) of Regulation S-K.

 

Mr. Fox will receive compensation for his service as a member of the Board in accordance with the Company’s Director Compensation Policy (the “Director Compensation Policy”), a copy of which is filed as Exhibit 10.17 to the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024 (the “Annual Report”). In accordance with the terms of the Director Compensation Policy, upon his appointment, Mr. Fox was granted an option to purchase 48,800 shares of the Company’s common stock. The option will vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.

In connection with his election, Mr. Fox entered into the Company’s standard form of indemnification agreement, a copy of which was filed as Exhibit 10.11 to the Annual Report. Pursuant to the terms of the indemnification agreement, the Company may be required to, among other things, indemnify Mr. Fox for certain expenses, including attorneys’ fees, judgments, penalties, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as a director of the Company.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on June 5, 2024. The certified results of the matters voted upon at the Annual Meeting, which are more fully described in the Company’s Proxy Statement for the Annual Meeting as filed with the SEC on April 26, 2024, are as follows (where applicable, voting results reflect fractional shares rounded down to the nearest whole share):

1. The Company’s stockholders elected the following nominees to the Company’s Board to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows:

For

Withheld

Broker
Non-Votes

Daniel R. Passeri

13,099,740

765,119

20,311,373

Frank Morich

7,990,004

5,605,204

20,581,024

Frederick Driscoll

12,486,167

1,378,692

20,311,373

Pamela Garzone

13,169,810

695,049

20,311,373

Peter A. Kiener

9,038,525

4,822,811

20,314,896

Patrick Verheyen

13,138,525

726,334

20,311,373

2. The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, with votes cast as follows:

For

Against

Abstain

32,418,349

1,635,231

122,652

3. The Company’s stockholders approved a non-binding advisory proposal on the compensation of the Company’s named executive officers, with votes cast as follows:

For

Against

Abstain

Broker

Non-Votes

11,745,009

1,924,707

195,143

20,311,373

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

Cue Biopharma, Inc.

 

 

 

Date: June 7, 2024

By:

/s/ Daniel R. Passeri

 

Name:

Daniel R. Passeri

 

Title:

Chief Executive Officer

 

 EX-101.SCH 2 cue-20240605.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Entity Addresses, Address Type [Axis] Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Document Information [Table] Entity Central Index Key Entity Address, State or Province Cover [Abstract] Entity Address, Address Line One Amendment Flag Entity Address, City or Town Document Type Title of 12(b) Security Address Type [Domain] Former Address [Member] Soliciting Material Entity Address, Address Line Two Document Period End Date Trading Symbol Pre-commencement Tender Offer Security Exchange Name Written Communications Pre-commencement Issuer Tender Offer Entity Registrant Name Entity Emerging Growth Company Entity File Number Entity Tax Identification Number City Area Code Local Phone Number Document Information [Line Items] XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
Jun. 05, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 05, 2024
Entity Registrant Name Cue Biopharma, Inc.
Entity Central Index Key 0001645460
Entity Emerging Growth Company false
Entity File Number 001-38327
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-3324577
Entity Address, Address Line One 40 Guest Street
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02135
City Area Code 617
Local Phone Number 949-2680
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CUE
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( 2 QU@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " $@,=8_-'IPNX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)^WJ"J&;B^))07!!\1:2V=U@TX1DI-VW-XV[740?0,@E,W^^ M^0;2Z2"TC_@@M(? M:H_08T8 ].APH05,WP.0\ M,1RGOH,+8(811I>^"V@68JG^B2T=8*?DE.R2&L>Q'E9]=?_A=A)TW=F?_ ML?%94';PZU_(+U!+ P04 " $@,=8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M 2 QU@2MS2#3P0 * 0 8 >&PO=V]R:W-H965T&UL MI9AM;Z-&$,>_RHI652LEX<'X(:EMR7&2:WJ7G!OG>E*KOEC#V%X=L'1WB9-O MWUEL@YOBP5+?Q"PP?WX[._QGR7 CU3>]!C#L-4TR/7+6QN17KJNC-:1<7\@< M,KRRE"KE!H=JY>I< 8_+H#1Q \_KN2D7F3,>EN=F:CR4A4E$!C/%=)&F7+U= M0R(W(\=W]B>>Q&IM[ EW/,SY"N9@ON0SA2.W4HE%"ID6,F,*EB-GXE]=!Z$- M*._X7.9XE@@0B8R4X_KS %)+$*B''WSM1IWJF#3P\ MWJO?E9/'R2RXAJE,OHK8K$?.P&$Q+'F1F">Y^05V$^I:O4@FNOS+-MM[P]!A M4:&-3'?!2)"*;/O+7W>). SPCP0$NX"@Y-X^J*2\X8:/ATINF+)WHYH]**=: M1B.[R%8!!A5@4.IUV@ /J-B?G_ N=F\@U7\U(6XE MPV9)6^A7.N<1C!RL9 WJ!9SQ#]_Y/>]G KA3 7V$W['D$UJ#"&IR"=9N"6HELQ3Y@O%FSJ4QS MGC7"T7IMA799<5V>PG4G$F"/1;H U<1":V">SCN#3M G>'RO-E;O%"(L!ZER MJ4KC.F-S@]7/I,*,%;BRN, R;JRY%O6;6PKRP/W]4R"?^2N[C['4Q%)$6XL] MGL06R;!_WND$8;=/IK&V?Y\TZSWA)([1JO79_H"5'>!SUIP[6C+TV(<"M,'% M4-@W*MT?(C_^6M"*7N!WNA1;W1S\%EQR% M%NCYY M0]P&?MN]/,L*0RO#P/>@.J _AU"_!IS_ZJA#&06=-/ MBVQG&+J1ZO^9OU^[OT];]UPF(A+&=J0'+&\E>-+(0ZNT\02U^0>T/<\4G$>8 M'L#W:[L9Q/T8*/9YN6Q>OQ:]5K+:\0/:GO]#=J]U@62M@+1L*^#!?I]VYV=A ML(?+)?.#'Q<_L3E$!=9;X]:B1>(*;M>^]"VSU+,?I M:MRTD=AU PAHQWY6/+;E-W]+%[*Q^%H$IE^HEA[4?A_0WKQ/&+M]C=8\6\'1 M;6V+T.-D?C/YK8G)/?C>M-_N#]QN!C5+8(E*WD4?35IM/X>W R/S\A-T(0U^ MT):':^!8;_8&O+Z4TNP']JNV^J?$^!]02P,$% @ !(#'6)^@&_"Q @ MX@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U" M\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.] MDKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"D ML<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#G MN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/ M\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T M\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]P MSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL M?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6P MQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y[' MNXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ M!(#'6)>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2 M:5K5N %(MB6/:(7->= MI3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8 M%II%R=.B':5_'36TGHX-R#8._AE8P=S8\? M=_<#4$L#!!0 ( 2 QU@D'INBK0 /@! : >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X* MMR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>L MXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " $@,=899!YDAD! #/ P $P %M#;VYT96YT M7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+; M,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R: MMB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT* M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87 M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( 2 QU@'04UB@0 M +$ 0 " 0 !D;V-0&UL4$L! A0# M% @ !(#'6/S1Z<+N *P( !$ ( !KP &1O8U!R M;W!S+V-O&UL4$L! A0#% @ !(#'6)E&PO=V]R:W-H965T M&UL4$L! A0#% @ !(#'6)^@&_"Q @ X@P T M ( !D@P 'AL+W-T>6QE&PO=V]R M:V)O;VLN>&UL4$L! A0#% @ !(#'6"0>FZ*M ^ $ !H M ( !Q!$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !J1( %M#;VYT96YT A7U1Y<&5S72YX;6Q02P4& D "0 ^ @ \Q, end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports cue-20240605.htm cue-20240605.xsd http://xbrl.sec.gov/dei/2024 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cue-20240605.htm": { "nsprefix": "cue", "nsuri": "http://www.cuebiopharma.com/20240605", "dts": { "inline": { "local": [ "cue-20240605.htm" ] }, "schema": { "local": [ "cue-20240605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_a6936314-8e69-43ec-8570-ab31acfcf5c7", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cue-20240605.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a6936314-8e69-43ec-8570-ab31acfcf5c7", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cue-20240605.htm", "first": true, "unique": true } } }, "tag": { "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r6", "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.cuebiopharma.com/20240605/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-070566-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-070566-xbrl.zip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end XML 14 cue-20240605_htm.xml IDEA: XBRL DOCUMENT 0001645460 2024-06-05 2024-06-05 0001645460 false 8-K 2024-06-05 Cue Biopharma, Inc. DE 001-38327 47-3324577 40 Guest Street Boston MA 02135 617 949-2680 false false false false Common Stock, par value $0.001 per share CUE NASDAQ false